Cargando…
RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report
Personalized medicine using molecular-targeted drugs to achieve better therapeutic response and long-term prognosis is common practice for lung cancer treatment. However, in cases before gene batch tests were available, medical treatment continued without the detection of rare mutations. We report a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702555/ https://www.ncbi.nlm.nih.gov/pubmed/36452495 http://dx.doi.org/10.3389/fonc.2022.1019932 |
_version_ | 1784839685657329664 |
---|---|
author | Morikawa, Kei Handa, Hiroshi Ueno, Junko Tsuruoka, Hajime Inoue, Takeo Shimada, Naoki Koike, Junki Nakamura, Seiji Sato, Yoshiharu Mineshita, Masamichi |
author_facet | Morikawa, Kei Handa, Hiroshi Ueno, Junko Tsuruoka, Hajime Inoue, Takeo Shimada, Naoki Koike, Junki Nakamura, Seiji Sato, Yoshiharu Mineshita, Masamichi |
author_sort | Morikawa, Kei |
collection | PubMed |
description | Personalized medicine using molecular-targeted drugs to achieve better therapeutic response and long-term prognosis is common practice for lung cancer treatment. However, in cases before gene batch tests were available, medical treatment continued without the detection of rare mutations. We report a sixty-seven-old year man diagnosed with adenocarcinoma T1cN3M1a, stage IVA. Initial screening performed 7 years earlier using EGFR mutation and ALK immunohistochemical tests were negative. Although first-line cytotoxic combination chemotherapy was remarkably effective, a gradual regression of the primary lesion was noted. After a recent bronchoscopic re-biopsy, RET fusion was detected by gene panel test. In addition, we were able to confirm RET from FFPE specimens obtained from 7-year-old pleural effusion cell blocks. Subsequent administration of the molecular-targeted drug selpercatinib, was highly effective for the primary lesion and all metastatic lesions including brain metastases. We describe a case of RET fusion-positive lung cancer where molecular targeted therapy and cytotoxic drug showed a drastic response and long-term therapy was well maintained. Next generation sequencing was able to correctly diagnose RET fusion mutation using re-biopsy specimen after going undiagnosed for 7 years. |
format | Online Article Text |
id | pubmed-9702555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97025552022-11-29 RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report Morikawa, Kei Handa, Hiroshi Ueno, Junko Tsuruoka, Hajime Inoue, Takeo Shimada, Naoki Koike, Junki Nakamura, Seiji Sato, Yoshiharu Mineshita, Masamichi Front Oncol Oncology Personalized medicine using molecular-targeted drugs to achieve better therapeutic response and long-term prognosis is common practice for lung cancer treatment. However, in cases before gene batch tests were available, medical treatment continued without the detection of rare mutations. We report a sixty-seven-old year man diagnosed with adenocarcinoma T1cN3M1a, stage IVA. Initial screening performed 7 years earlier using EGFR mutation and ALK immunohistochemical tests were negative. Although first-line cytotoxic combination chemotherapy was remarkably effective, a gradual regression of the primary lesion was noted. After a recent bronchoscopic re-biopsy, RET fusion was detected by gene panel test. In addition, we were able to confirm RET from FFPE specimens obtained from 7-year-old pleural effusion cell blocks. Subsequent administration of the molecular-targeted drug selpercatinib, was highly effective for the primary lesion and all metastatic lesions including brain metastases. We describe a case of RET fusion-positive lung cancer where molecular targeted therapy and cytotoxic drug showed a drastic response and long-term therapy was well maintained. Next generation sequencing was able to correctly diagnose RET fusion mutation using re-biopsy specimen after going undiagnosed for 7 years. Frontiers Media S.A. 2022-11-14 /pmc/articles/PMC9702555/ /pubmed/36452495 http://dx.doi.org/10.3389/fonc.2022.1019932 Text en Copyright © 2022 Morikawa, Handa, Ueno, Tsuruoka, Inoue, Shimada, Koike, Nakamura, Sato and Mineshita https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Morikawa, Kei Handa, Hiroshi Ueno, Junko Tsuruoka, Hajime Inoue, Takeo Shimada, Naoki Koike, Junki Nakamura, Seiji Sato, Yoshiharu Mineshita, Masamichi RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report |
title |
RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report |
title_full |
RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report |
title_fullStr |
RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report |
title_full_unstemmed |
RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report |
title_short |
RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report |
title_sort | ret fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702555/ https://www.ncbi.nlm.nih.gov/pubmed/36452495 http://dx.doi.org/10.3389/fonc.2022.1019932 |
work_keys_str_mv | AT morikawakei retfusionmutationdetectedbyrebiopsy7yearsafterinitialcytotoxicchemotherapyacasereport AT handahiroshi retfusionmutationdetectedbyrebiopsy7yearsafterinitialcytotoxicchemotherapyacasereport AT uenojunko retfusionmutationdetectedbyrebiopsy7yearsafterinitialcytotoxicchemotherapyacasereport AT tsuruokahajime retfusionmutationdetectedbyrebiopsy7yearsafterinitialcytotoxicchemotherapyacasereport AT inouetakeo retfusionmutationdetectedbyrebiopsy7yearsafterinitialcytotoxicchemotherapyacasereport AT shimadanaoki retfusionmutationdetectedbyrebiopsy7yearsafterinitialcytotoxicchemotherapyacasereport AT koikejunki retfusionmutationdetectedbyrebiopsy7yearsafterinitialcytotoxicchemotherapyacasereport AT nakamuraseiji retfusionmutationdetectedbyrebiopsy7yearsafterinitialcytotoxicchemotherapyacasereport AT satoyoshiharu retfusionmutationdetectedbyrebiopsy7yearsafterinitialcytotoxicchemotherapyacasereport AT mineshitamasamichi retfusionmutationdetectedbyrebiopsy7yearsafterinitialcytotoxicchemotherapyacasereport |